1. Crizotinib (Xalkori®) Medical Review NDA 202570, FDA Sept 2011.
2. Crizotinib (Xalkori®) Pharmacological Review NDA 202570, FDA Mar 2011.
3. Xalkori® (crizotinib) Prescribing Information, Pfizer Mar 2015.
4. Xalkori® (crizotinib) Accelerated Approval Letter, FDA Feb 2011.
5. FDA Approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphomakinase rearrangements;Kazandjian;Oncologist,2014